Claims for Patent: 8,784,878

Summary for Patent: 8,784,878

Title:	Transdermal delivery rate control using amorphous pharmaceutical compositions
Abstract:	A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (C.sub.max) to the average concentration (C.sub.avg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
Inventor(s):	Morgan; Timothy Matthias (Carlton North, AU), Wilkins; Nina Frances (Kensington, AU), Klose; Kathryn Traci-Jane (Bonreach, AU), Finnin; Barrie Charles (Toorak, AU), Reed; Barry Leonard (Essendon, AU)
Assignee:	Acrux DDS Pty Ltc. (West Melbourne, Victoria, AU)
Application Number:	13/710,761
Patent Claims:	1. A non-occlusive transdermal pharmaceutical composition for the transdermal delivery of testosterone, comprising: (a) from 0.1% to 10% by weight of testosterone; (b) from 0.1% to 10% by weight of one or more dermal penetration enhancers selected from the group consisting of octyl salicylate and Padimate O; and (c) from 85% to 99.8% by weight of a volatile solvent selected from the group consisting of ethanol, isopropanol, and mixtures thereof; wherein the combination of testosterone and dermal penetration enhancer(s) is such that the composition, upon application and evaporation of the solvent at physiological temperatures, forms an amorphous deposit comprising an amorphous phase containing the dermal penetration enhancer(s) and testosterone. 2. A composition according to claim 1, wherein the molar ratio of testosterone to dermal penetration enhancer is from 1:20 to 20:1. 3. A composition according to claim 1, wherein the composition consists of the testosterone, the penetration enhancer(s), the volatile solvent(s) and, optionally, a gelling agent. 4. A composition according to claim 1, wherein the penetration enhancer is octyl salicylate. 5. A non-occlusive pharmaceutical composition for transdermal delivery of testosterone, consisting of: (a) from 0.1% to 10% by weight of testosterone; (b) from 0.1% to 10% by weight of one or more dermal penetration enhancers selected from the group consisting of octyl salicylate and Padimate O; and (c) from 85% to 99.8% by weight of a volatile solvent selected from the group consisting of ethanol, isopropanol, and mixtures thereof; and (d) optionally a gelling agent; wherein the combination of testosterone and dermal penetration enhancer(s) is such that the composition, upon application and evaporation of the solvent at physiological temperatures, forms an amorphous deposit comprising an amorphous phase, containing the dermal penetration enhancer(s) and testosterone. 6. A method of transdermally delivering testosterone to a subject in need thereof, comprising applying a composition according to claim 1 to the skin of the subject. 7. The method of claim 6, wherein the composition consists of the testosterone, the penetration enhancer(s), the volatile solvent(s) and, optionally, a gelling agent.